Genomics of Drug Sensitivity in Cancer |
Gefitinib
|
Synonyms |
ZD-1839, Iressa
|
Targets |
EGFR
|
Target pathway |
EGFR signaling
|
PubCHEM ID |
123631
|
Jsmol |
|
Download molecule |
123631
|
PUBCHEM IUPAC INCHI |
InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
|
Smiles |
ClC1(=C(F)C=CC(=C1)NC2(=NC=NC=4(C2=CC(OCCCN3(CCOCC3))=C(C=4)OC)))
|
Cluster number |
115
|
calculated LogS |
-5,062
|
Molecular weight |
446,909
|
calculated LogP |
3,9851
|
H-Acceptors |
7
|
H-Donors |
1
|
Ro5 violations |
0
|
Druglikeness |
0,47937
|
DrugScore |
0,430463988038668
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Fish Toxicity |
High FHMT
|
Fish Toxicity2 |
1,3361
|
Rat Acute Toxicity |
2,5141
|
Acute Oral Toxicity |
III
|
Caco-2 Permeability |
Caco2+
|
Caco-2 Permeability2 |
0,9275
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Inhibitor
|
P-glycoprotein Inhibitor2 |
Inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition |
Strong inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition2 |
Inhibitor
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity2 |
0,4803
|
AMES Toxicity |
Non AMES toxic
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 3A4 Inhibitor |
Inhibitor
|
CYP450 2C19 Inhibitor |
Inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 1A2 Inhibitor |
Inhibitor
|
CYP450 2D6 Substrate |
Non-substrate
|
Biodegradation |
Not ready biodegradable
|
Carcinogenicity (Three-class) |
Non-carcinogens
|
Carcinogens |
Non-required
|
Blood-Brain Barrier |
BBB+
|
CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
Honey Bee Toxicity |
Low HBT
|
Renal Organic Cation Transporter |
Inhibitor
|
Subcellular localization |
Lysosome
|
Human Intestinal Absorption |
HIA+
|
Aqueous solubility |
-3,5951
|